SOTIO Biotech

Zuzana Antosova, our Director of Bioanalysis & Pharmacokinetics, will present on the preclinical development of our anti-Claudin 18.2 ADC and its transition into clinical pharmacokinetics at the Hanson Wade Group’s ADC Pharmacokinetics & Clinical Pharmacology Summit. #Biotechnology #ADCs #CancerResearch #jsmePPF

Coming up at the Global IP Strategy Hub’s Life Sciences Strategy Summit on IP & Exclusivity, our Head of IP, Christoph Rehfuess, will join the “Patent Quality Review: How Does this Affect your IP Strategy?” panel. The panel is focused on the concern of the life science industry regarding patent quality and an effective IP marketplace, the involvement of life science companies at the IPQC, the EPO’s efforts to enhance patent quality, and more. Learn more here: https://bit.ly/4gw0Lw5 #LifeSciences #jsmePPF

We’re proud to share that Jitka Fucikova, Senior Scientist, was honored with the prestigious Czech Woman (Žena Česka) 2024 Award, presented by CNN Prima News TV. This award recognizes women who make significant contributions to improving lives both in the Czech Republic and around the world. Jitka was chosen from almost 1500 of nominations by an expert panel for her outstanding contributions in immunology and cancer immunotherapy.    Jitka was also featured in Forbes Česko article showcasing the 24 top female scientists: https://bit.ly/4gMBuxQ   We’re grateful to have such a talented and devoted scientist like Jitka leading our team. Read more about her remarkable work in her exclusive interview: https://bit.ly/47QXJie #WomenInSTEM #immunotherapy #CancerResearch #jsmePPF

Breast cancer is the second most common cancer worldwide according to IARC - International Agency for Research on Cancer / World Health Organization. As we honor #BreastCancerAwarenessMonth, we remain committed to pioneering new treatments for patients suffering from breast #cancer and other solid tumors. #BreastCancerAwareness #BreastCancer #jsmePPF

We recently concluded a six-month internship program hosting Master’s students from various institutions within the 4EU+ Alliance, facilitated by the Erasmus Plus program. Our interns had the opportunity to participate in cutting-edge tumor #immunology #research under the mentorship of scientists from Charles University and SOTIO. Their research included hands-on experience with advanced techniques such as digital pathology and molecular sequencing, contributing to projects that have the potential to transform #cancer therapies. In a recent Charles University magazine article, our interns share their experiences in the lab and the impactful outcomes of their work, highlighting the potential for publishing their findings in prestigious scientific journals. We’re proud to foster this collaboration and look forward to inspiring more students! https://bit.ly/3BlD2yR #cancerresearch #jsmePPF

World Cancer Research Day is a chance to reflect on the vital role that innovation and research play in the advancement of #cancer treatments. At SOTIO, we’re developing new therapies for patients with solid tumors that have limited or no targeted treatment options. We are proud to contribute to the global effort to advance treatment options for all people facing cancer. #WorldCancerResearchDay #immunotherapy #cancerresearch #jsmePPF

This week SOTIO will join fellow industry leaders at Prague.bio, a time to exchange experiences and information among professionals in Central Europe involved in the development of new therapeutic options for patients. #biotechnology #cancerresearch #jsmePPF

Today at SOTIO Biotech we hosted a group of experienced professionals and students of the MBA program focused on healthcare from the University of St. Thomas (Minnesota, US). It was exactly five years since their last visit. Jitka Fucikova and I presented SOTIO and our R&D activities, Kateřina Hlavsová and Jakub Macošek guided our guests through the research laboratories, and together we all answered a lot of inquisitive questions. Thank you for the inspiring discussion!

SOTIO is currently advancing three clinical studies for our investigational #cancer therapies at leading research institutions around the world. Currently in Phase 1/2 in the U.S. and Europe is our lead #ADC candidate SOT102. Our enhanced CAR T-cell therapy, BOXR1030, is in Phase 1/2 trials in the U.S. And we recently initiated a Phase 1 trial of SOT201, a next-generation PD-1 targeting immunocytokine. Learn more information about our ongoing trials here: https://bit.ly/3AE1RW8 #biotechnology #clinicaltrials #cancerresearch #jsmePPF

New findings from the SOTIO research team, featured in the American Association for Cancer Research’s Clinical Cancer Research Journal, highlight the promising role of neo-adjuvant chemotherapy in treating #ovariancancer. This latest research demonstrates the impact of combining chemotherapy with immune checkpoint inhibitors, and how it can enhance the treatment of ovarian #cancer by boosting tertiary lymphoid structures development and immune cell activity in tumors. This approach may offer a more effective strategy for targeting this disease and optimizing treatment outcomes. Read more here: https://bit.ly/4ebv2hY #ClinicalCancerResearch #oncology #immunotherapy #jsmePPF